Table 1 Associations between the expression levels of LAPTM4B and clinicopathological characteristics in 63 LAC patients
Characteristics | Number | Expression of LAPTM4B | P value | |
|---|---|---|---|---|
Low(n = 15) | High(n = 48) | |||
Gender | ||||
 Male | 21(33.33%) | 5 | 16 | 1.000 |
 Female | 42(66.67%) | 10 | 32 | |
Age | Â | |||
  ≤ 60 | 20(31.75%) | 3 | 17 | 0.349 |
  > 60 | 43(68.25%) | 12 | 31 | |
Smoking | ||||
 No | 48(76.2%) | 12 | 36 | 1.000 |
 Yes | 15(23.8%) | 3 | 12 | |
Hypertension | ||||
 No | 41(65.1%) | 10 | 31 | 0.883 |
 Yes | 22(34.9%) | 5 | 17 | |
Depth of infiltration | ||||
 T1 + T2 | 59(93.65%) | 15 | 44 | 0.564 |
 T3 + T4 | 4(6.35%) | 0 | 4 | |
Clinical stages | ||||
 I + II | 50(79.37%) | 15 | 35 | 0.027 |
 III + IV | 13(20.63%) | 0 | 13 | |
Lymph nodes status | ||||
 No | 42(66.67%) | 14 | 28 | 0.012 |
 Yes | 21(33.33%) | 1 | 20 | |
Tumor size | ||||
  < 3 cm | 43(68.25%) | 13 | 30 | 0.114 |
  ≥ 3 cm | 20(31.75%) | 2 | 18 | |
EGFR mutations | ||||
 Negative | 32(50.79%) | 14 | 18 | < 0.001 |
 Positive | 31(49.21%) | 1 | 30 | |
K-ras mutations | ||||
 Negative | 58(92.06%) | 13 | 45 | 0.585 |
 Positive | 5(7.94%) | 2 | 3 | |